Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries

Vaccine

Volumn 22, Issue 1, 2003, Pages 121-129

  DeRoeck, Denise ^a,b   Deen, Jacqueline ^a   Clemens, John D ^a  

^a International Vaccine Institute   (South Korea)

^b NONE   (United States)

Author keywords

Dengue dengue haemorrhagic fever; Policymaking; Vaccines

Indexed keywords

DENGUE VACCINE;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DENGUE; DISEASE SEVERITY; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; GOVERNMENT; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HOSPITAL; HUMAN; IMMUNIZATION; INFECTION RISK; INTERVIEW; PRIORITY JOURNAL; PUBLIC HEALTH; RECURRENCE RISK; REVIEW; SOUTHEAST ASIA;

EID: 0242321179     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00533-4     Document Type: Article

References (28)

1. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10(2):2002;100-103.
2. Solomon T., Mallewa M. Dengue and other emerging flaviviruses. J. Infect. 42:2001;104-115.
3. Isturiz R.E., Gubler D.J., Brea del Castillo J. Dengue and dengue hemorrhagic fever in Latin America and the Caribbean. Infect. Dis. Clin. North Am. 14(1):2000;121-140.
4. Jacobs M. Current issues in tropical paediatric infection diseases: dengue. Emergence as a global public health problem. Trans. R. Soc. Trop. Med. Hyg. 94:2000;7-8.
5. World Health Organization. Social mobilization and communication for dengue fever prevention and control: a guide on achieving and sustaining behavioural results. Geneva, Switzerland: World Health Organization [draft report]
6. Rigau-Pérez J.G., Clark G.G., Gubler D.J., Reiter P., Sangers E.J., Vorndam A.V. Dengue and dengue haemorrhagic fever. Lancet. 352:1998;971-977.
7. Halstead S.B. Pathogenesis of dengue: challenges to molecular biology. Science. 239:1988;476-481.
8. Vaughn D.W., Green S., Kalyanarooj S.et al. Dengue viremia titer, antibody response pattern and virus serotype correlate with disease severity. J. Infect. Dis. 181:1999;2-9.
9. Shope R.E. Concepts of control of Japanese encephalitis and dengue. Southeast Asian J. Trop. Med. Public Health. 28(Suppl. 2):1997;131-134.
10. Halstead S.B., Deen J. The future of dengue vaccines. Lancet. 360:2002;1243-1245.
11. Kanesa-thasan N., Sun W., Kim-Ahn G.et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine. 19:2001;3179-3188.
12. Bhamarapravati N., Yoksan S. Live-attenuated tetravalent dengue vaccine. Vaccine. 18(Suppl. 2):2000;44-47.
13. Edelman R., Tacket C.O., Wasserman S.S.et al. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J. Infect. Dis. 170:1994;1448-1455.
14. Guirkhoo F., Arroyo J., Pugachev K.V.et al. Construction, safety, and immunogenicity in non-human primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75:2001;7290-7304.
15. Huang C.Y., Butrapet S., Pierro D.J.et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J. Virol. 74:2000;3020-3028.
16. Kinney R.M., Huang C.Y. Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology. 44:2001;176-197.
17. Durbin A.P., Karron R.A., Sun W.et al. Attenuation and immunogenicity in humans of a live dengue virus type 4 vaccine candidate with a 30 nucleotide deletion in its 3′ untranslated region. Am. J. Trop. Med. Hyg. 65:2001;405-413.
18. Markoff L., Pang X., Houng H.S.et al. Derivation and characterization of a dengue 1 host-range restricted mutant virus that is attenuated and highly immunogenic in monkeys. J. Virol. 76:2002;3318-3328.
19. World Health Organization. Strengthening implementation of the global strategy for dengue fever/dengue hemorrhagic fever prevention and control. Report of an informal consultation. Geneva, Switzerland: World Health Organization; 1999.
20. Madrid MY. The introduction and use of new vaccines in the public and private sectors: Thailand. Global programme on vaccines and immunization. Geneva, Switzerland: World Health Organization; 1998 [draft report].
21. Madrid MY. The introduction and use of new vaccines in the public and private sectors: Morocco. Global programme on vaccines and immunization. Geneva, Switzerland: World Health Organization; 1998 [draft report].
22. Madrid MY. Summary of three country studies on the introduction of new vaccines (Morocco, Thailand, Zimbabwe). Global programme on vaccines and immunization. Geneva, Switzerland: World Health Organization; 1998 [draft report].
23. Princeton Survey Research Associates. Benchmark surveys on childhood immunization in Thailand, Nepal, Zimbabwe and Tanzania. Washington, DC: Princeton Survey Research Associates; 1999 [draft report].
24. DeRoeck D, Nyamete A, Mahoney RT, Clemens JD. Policymakers' views regarding the introduction of new generation enteric vaccines in Asia [draft report].
25. Cardosa M.J. Dengue vaccine design: issues and challenges. Br. Med. Bull. 54:1998;395-405.
26. Ministry of Health, Indonesia. DHF prevention and control program in Indonesia. Arbovirosis Subdirectorate, Directorate of Vector-Borne Disease Control, Directorate General for Communicable Disease Control and Environmental Health; 2002 [unpublished report].
27. Ivanoff B., Levine M.M., Lambert P.H. Vaccination against typhoid fever: present status. Bull. WHO. 72(6):1994;957-971.
28. Kotloff A.L., Winickoff J.P., Ivanoff B.et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. WHO. 77(8):1999;651-666.